AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01785966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily checklist and clinician prompting
Description: Interventions are:~Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.~Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items.
Study NCT01992380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart
Study NCT01992380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection
Study NCT01413568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Study NCT01413568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Study NCT01413568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC Transplant
Study NCT01983748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cells loaded with autologous Tumor RNA
Study NCT03671005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy
Description: see above
Study NCT03671005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: see above
Study NCT05418036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sotalol Oral Tablet
Description: Dose of sotalol is prescribed by the attending physician. Accepted for this protocol when the dose is no greater than 160 mg/day
Study NCT03118583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg/day of dietary supplement containing carrageenan
Description: 300 mg/day of dietary supplement containing carrageenan.
Study NCT01420055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod
Study NCT02605486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Study NCT02605486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Study NCT04960111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RSA
Description: application of tantalium microsphere around knee prosthesis and RSA X-ray post operative to detect early mobilization in follow up.
Study NCT03907124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genetically-guided treatment with FDA-approved psychotropic drugs
Description: Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications
Study NCT03907124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
Study NCT04041960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.
Study NCT04041960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Description: The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.
Study NCT00598429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Prostaglandin E1
Description: Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
Study NCT00598429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Prostaglandin E1
Description: Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
Study NCT04294966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: Administering dextrose to healthy volunteers for our placebo group
Study NCT04294966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users.
Study NCT04292626 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPECT with 99mTc-1-thio-D-glucose
Description: One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
Study NCT04432987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme
Description: PULMOZYME contains an active substance called dornase alpha as an active substance. Dornase alpha is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.~Drug will be administered at a dose of 2,5 mg/2 times per day for 7 days
Study NCT04678492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet TID plus amoxicillin 500 mg 2 capsules TID
Study NCT04678492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: High-dose esomeprazole and amoxicillin dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 40mg 1 tablet TID
Study NCT04678492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 40 mg 1 tablets BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
Study NCT04678492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 40mg 1 tablet BID plus bismuth 110 mg 2 capsules BID，tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
Study NCT04678492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
Study NCT04678492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furazolidone
Description: Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID，esomeprazole 40 mg 1 tablets BID and bismuth 110 mg 2 capsules BID
Study NCT00965224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell vaccination (active specific immunotherapy)
Study NCT00925613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Proseal
Description: Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.~If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube.
Study NCT00925613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal tube
Description: Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for \<12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
Study NCT00408213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1g po bid
Study NCT00408213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid
Study NCT03433001 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study NCT01280370 — intervention group
Intervention type: PROCEDURE
Intervention: Abdominal surgery
Description: intraoperative mesh implantation
Study NCT00130533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT03365024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy for Insomnia
Description: A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
Study NCT03365024 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: A web-based program will deliver components of sleep education via an Internet platform
Study NCT02509871 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Body composition measurement
Description: DXA, impedance
Study NCT01186978 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: 1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
Study NCT01685970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High volume split-dose PEG
Description: High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy
Study NCT01685970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 sachets of picosulfate
Description: 2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
Study NCT04193800 — intervention group
Intervention type: OTHER
Intervention: 10-week rotation in primary care setting
Description: Ten paramedics underwent a 10 week rotation into a GP practice in the Leeds area of South Yorkshire, England.
Study NCT03901326 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT-FFR assessment
Description: When subjects are randomized to the CTA/CT-FFR arm, FFR based on the coronary CTA imaging will be measured. DEEPVESSEL FFR workstation is very dedicated software utilizing the original CTA imaging to meter simulated FFR values based on a machine learning algorithm. The first step is to extract a 3D coronary artery model and generate coronary centerlines which are similar to the routine reconstruction of coronary CTA. The centerlines are extracted using a minimal path extraction filter. Then a novel path-based deep learning model, referred to DEEPVESSEL FFR, is used to predict the simulated FFR values on the vascular centerlines. Deep learning algorithm is used to establish characteristic sample database of coronary hemodynamics characteristic parameters. When deep training model is proved to be valid, it is applied to a new lesion-specific measurement. Lesion-specific CT-FFR is defined as simulated FFR value at distance of 20mm away from the lesion of interest.
Study NCT03058211 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Standard protocols
Study NCT03058211 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic resonance
Description: MRI with late gadolinium increase and T1 mapping
Study NCT03939377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire and treatment
Description: EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5
Study NCT03939377 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire and treatment
Description: EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5
Study NCT00006213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-214662
Description: Given IV
Study NCT00006213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00006213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02385305 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pressure support ventilation by anesthesia machine (Apollo, Dräger)
Description: Pressure support ventilation will be applied by anesthesia machine (Apollo, Dräger) with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the Pressure support ventilation is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS.
Study NCT02869087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Akesys Prava Scaffold
Description: Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System
Study NCT03927950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: escitalopram 10-20mg per day 12 weeks
Study NCT03927950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: bupropion 150-300mg per day 6 weeks
Study NCT03443882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: an oral dose form
Study NCT03443882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: an oral dose form
Study NCT04025385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training
Description: Training for 25 min with four 1 minute intervals when participants exercise up to 80% of their individual limits.
Study NCT04654728 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Active Comparator: ePTFE graft
Description: In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
Study NCT04654728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: ePTFE graft
Description: In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
Study NCT02967133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Arm A: Nivolumab 240 mg via intravenous infusion (IV) over 30 minutes day 1 of each 14 day cycle until disease progression or not tolerated.~Arm B: Nivolumab 360 mg via intravenous infusion (IV) over 30 minutes day 1 of every 21 day treatment cycle until progression or not tolerated.
Study NCT02967133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Patients in arm B receive nab-paclitaxel at a dose of 100 mg/m2 over intravenous infusion on Days 1 and 8 of each 21 day cycle.
Study NCT02976012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: . Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
Study NCT02976012 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endolaserless Vitrectomy
Description: Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
Study NCT00701428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 50 mg daily during 6 + 6 weeks
Study NCT00701428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 50 mg daily during 6 + 6 weeks
Study NCT03945188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
Study NCT03945188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
Study NCT04530448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
Study NCT04530448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care treatment
Study NCT06410677 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DNA Sequencing, RNA Sequencing
Description: High-coverage Whole-Exome Sequencing sequencing of DNA samples from ESCC was performed.~RNA expression was analyzed using the NanoString PanCancer Immuno-Oncology 360TM Panel that includes a set of more than 700 genes involved in the main biological pathways of human immunity. These experiments were performed by the Genomics platform of Institut Curie. Total RNAs were used as templates.
Study NCT00701428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP during the second 6 week-period
Study NCT03760133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duolac
Description: Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
Study NCT00542516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch
Description: Dosage: 30ml/kg; frequency: one time; duration: 60min
Study NCT00542516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethyl Starch
Description: Dosage: 30ml/kg; frequency: one time; duration: 60min
Study NCT00542516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
Study NCT04585555 — intervention group
Intervention type: DEVICE
Intervention: Accuryn Monitoring System
Description: The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
Study NCT00310856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.
Study NCT00310856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-CRM
Description: One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
Study NCT01558557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten Free Diet
Description: Participants will be given a Gluten Free Diet for 2 weeks
Study NCT05130541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proning
Description: Rotating on long axis 90 degrees every 30 minutes